The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -8.14 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -2.17 — no flag raisedOK
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Esperion Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Collaboration Revenue$243.6M
- Product$159.6M
- Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received$148.8M
Leadership changes
From Esperion Therapeutics, Inc.'s own filings, the day they're filed.
- John B. Harlow Jr · appointmenteff. 2025-11-17
- Eric Warren · Chief Commercial Officer · departureeff. 2025-04-18
- JoAnne Foody · Chief Medical Officer · departureeff. 2024-08-05
Latest filings
- 8-K · Company announcement2026-06-16
- 8-K · Company announcement2026-06-09
- 8-K · Company announcement2026-06-01
- 10-Q · Quarterly report2026-05-08
- 8-K · Company announcement2026-05-01
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about Esperion Therapeutics, Inc., every answer cited🔒
- The Intelligence Brief — added when Esperion Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.